Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

December 01, 2008 (Vol. 28, No. 21)

Status of Biosimilars in U.S. Could Soon Change

Review of the Technical and Legal Issues Delaying Approval of Generic Biologics

  • Biologics are one of the fastest growing and most expensive categories of drugs. They typically cost 20 times more per patient per day than traditional small molecule drugs. By 2009, U.S. sales alone are estimated to reach $90 billion and by 2010, approximately $10 billion worth of biopharmaceutical drugs ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.